Nektar Therapeutics (NASDAQ:NKTR) Expected to Earn Q4 2024 Earnings of ($0.26) Per Share

Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at Zacks Research upped their Q4 2024 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a report released on Tuesday, August 6th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn ($0.26) per share for the quarter, up from their prior estimate of ($0.27). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.84) per share.

Separately, Rodman & Renshaw assumed coverage on Nektar Therapeutics in a report on Friday, June 28th. They set a “buy” rating and a $2.00 price target for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $1.50.

Nektar Therapeutics Price Performance

NASDAQ:NKTR traded down $0.10 during trading hours on Thursday, reaching $1.11. 1,130,121 shares of the stock were exchanged, compared to its average volume of 1,991,905. Nektar Therapeutics has a twelve month low of $0.41 and a twelve month high of $1.93. The firm has a 50 day moving average of $1.28 and a 200 day moving average of $1.16. The stock has a market cap of $204.26 million, a PE ratio of -1.21 and a beta of 0.66.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. Nektar Therapeutics had a negative return on equity of 107.31% and a negative net margin of 195.02%. The firm had revenue of $21.64 million during the quarter, compared to the consensus estimate of $14.91 million. During the same quarter in the prior year, the firm posted ($0.25) EPS.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Monaco Asset Management SAM increased its position in shares of Nektar Therapeutics by 24.2% in the fourth quarter. Monaco Asset Management SAM now owns 5,973,387 shares of the biopharmaceutical company’s stock worth $3,375,000 after purchasing an additional 1,163,786 shares during the period. GSA Capital Partners LLP grew its position in Nektar Therapeutics by 185.5% in the fourth quarter. GSA Capital Partners LLP now owns 5,255,790 shares of the biopharmaceutical company’s stock valued at $2,970,000 after acquiring an additional 3,414,712 shares during the last quarter. Lynx1 Capital Management LP boosted its stake in shares of Nektar Therapeutics by 7.2% during the first quarter. Lynx1 Capital Management LP now owns 2,068,842 shares of the biopharmaceutical company’s stock valued at $1,933,000 after purchasing an additional 139,644 shares in the last quarter. Acuitas Investments LLC boosted its stake in shares of Nektar Therapeutics by 26.3% during the fourth quarter. Acuitas Investments LLC now owns 911,204 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 189,744 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Nektar Therapeutics by 2,822.5% in the second quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock valued at $684,000 after acquiring an additional 532,663 shares during the last quarter. Institutional investors own 75.88% of the company’s stock.

Insider Buying and Selling at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 16,650 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $1.75, for a total transaction of $29,137.50. Following the transaction, the chief executive officer now owns 863,239 shares in the company, valued at approximately $1,510,668.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 43,505 shares of company stock valued at $65,409 in the last quarter. 3.71% of the stock is currently owned by insiders.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.